Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 374 participants.

Also called NCT02790632

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 374 participants (planned count) (from the registry)
Sponsor
Edge Therapeutics Inc (from the registry)
Registry
  • NCT NCT02790632
Other papers using this trial's data
  • Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage Stroke, 2020-04 DOI, PubMed 32138631

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Austria, Canada, Czechia, Finland, Germany, Hong Kong SAR China, Israel, New Zealand, Singapore (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02790632. Randomized; quadruple masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2018-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
Acronym
NEWTON2
Condition
Subarachnoid Hemorrhage, Aneurysmal
Intervention (Drug)
EG-1962 (nimodipine microparticles)
Intervention (Drug)
Enteral Nimodipine
Lead sponsor
Edge Therapeutics Inc (class: industry)

Record details

Record id
cardio:ct-nct02790632
Content hash
68e318249bfeb89f77e6192a08fa89cb633ef661cb1e7b556479e760270fb271